Special Issue "COVID-19: Antivirals and Vaccines"

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: 30 September 2021.

Special Issue Editor

Prof. Dr. Oliver Schildgen
E-Mail Website
Guest Editor
Institut für Pathologie, Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke mit Sitz in Köln, Ostmerheimer Str. 200, D-51109 Köln (Cologne), Germany
Interests: human bocavirus (HBoV); Herpes simplex Virus; Respiratory viruses; viruses and cancer

Special Issue Information

Dear Colleagues,

We are pleased to announce the launch of a new Topical Collection entitled "COVID-19: Antivirals and Vaccines". This Special Issue aims to provide new insights into the broad topic of COVID-19 vaccine development and its application. We consider that this collection will be the best forum for disseminating excellent research findings as well as sharing innovative ideas in the field.

You are welcome to send a tentative title and a short abstract to our Editorial Office ([email protected]) for evaluation before submission. Please note that selected full papers will still be subject to a thorough and rigorous peer review.

We look forward to receiving your excellent work.

Prof. Dr. Oliver Schildgen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
Microorganisms 2021, 9(6), 1340; https://doi.org/10.3390/microorganisms9061340 - 21 Jun 2021
Cited by 1 | Viewed by 653
Abstract
Background: Little is known about potential confounding factors influencing the humoral response in individuals having received the BNT162b2 vaccine. Methods: Blood samples from 231 subjects were collected before and 14, 28, and 42 days following coronavirus disease 2019 (COVID-19) vaccination with BNT162b2. Anti-spike [...] Read more.
Background: Little is known about potential confounding factors influencing the humoral response in individuals having received the BNT162b2 vaccine. Methods: Blood samples from 231 subjects were collected before and 14, 28, and 42 days following coronavirus disease 2019 (COVID-19) vaccination with BNT162b2. Anti-spike receptor-binding-domain protein (anti-Spike/RBD) immunoglobulin G (IgG) antibodies were measured at each time-point. Impact of age, sex, childbearing age status, hormonal therapy, blood group, body mass index and past-history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were assessed by multivariable analyses. Results and Conclusions: In naïve subjects, the level of anti-Spike/RBD antibodies gradually increased following administration of the first dose to reach the maximal response at day 28 and then plateauing at day 42. In vaccinated subjects with previous SARS-CoV-2 infection, the plateau was reached sooner (i.e., at day 14). In the naïve population, age had a significant negative impact on anti-Spike/RBD titers at days 14 and 28 while lower levels were observed for males at day 42, when corrected for other confounding factors. Body mass index (BMI) as well as B and AB blood groups had a significant impact in various subgroups on the early response at day 14 but no longer after. No significant confounding factors were highlighted in the previously infected group. Full article
(This article belongs to the Special Issue COVID-19: Antivirals and Vaccines)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Back to TopTop